Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

662 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Reductions in remnant cholesterol and VLDL cholesterol through inhibition of ANGPTL3 protein synthesis: an analysis from the TRANSLATE-TIMI 70 trial.
Zimerman A, Wiviott SD, Park JG, Murphy SA, Ran X, Bramson CR, Curto M, Ramos V, Jevne A, Kuder JF, Verma S, Wojakowski W, Terra SG, Sabatine MS, Bergmark BA, Marston NA. Zimerman A, et al. Among authors: murphy sa. Eur J Prev Cardiol. 2024 Mar 14:zwae090. doi: 10.1093/eurjpc/zwae090. Online ahead of print. Eur J Prev Cardiol. 2024. PMID: 38484368
Effect of Vupanorsen on Non-High-Density Lipoprotein Cholesterol Levels in Statin-Treated Patients With Elevated Cholesterol: TRANSLATE-TIMI 70.
Bergmark BA, Marston NA, Bramson CR, Curto M, Ramos V, Jevne A, Kuder JF, Park JG, Murphy SA, Verma S, Wojakowski W, Terra SG, Sabatine MS, Wiviott SD; TRANSLATE-TIMI 70 Investigators. Bergmark BA, et al. Among authors: murphy sa. Circulation. 2022 May 3;145(18):1377-1386. doi: 10.1161/CIRCULATIONAHA.122.059266. Epub 2022 Apr 3. Circulation. 2022. PMID: 35369705 Free PMC article. Clinical Trial.
Hemodynamic significance of periprocedural myocardial injury assessed with N-terminal pro-B-type natriuretic peptide after percutaneous coronary intervention in patients with stable and unstable coronary artery disease (from the JUMBO-TIMI 26 trial).
Bonaca MP, Wiviott SD, Sabatine MS, Buros J, Murphy SA, Scirica BM, Rifai N, Antman EM, Morrow DA. Bonaca MP, et al. Among authors: murphy sa. Am J Cardiol. 2007 Feb 1;99(3):344-8. doi: 10.1016/j.amjcard.2006.08.035. Epub 2006 Nov 30. Am J Cardiol. 2007. PMID: 17261395 Clinical Trial.
Seasonal variation in lipids in patients following acute coronary syndrome on fixed doses of Pravastatin (40 mg) or Atorvastatin (80 mg) (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22 [PROVE IT-TIMI 22] Study).
Tung P, Wiviott SD, Cannon CP, Murphy SA, McCabe CH, Gibson CM. Tung P, et al. Among authors: murphy sa. Am J Cardiol. 2009 Apr 15;103(8):1056-60. doi: 10.1016/j.amjcard.2008.12.034. Epub 2009 Feb 21. Am J Cardiol. 2009. PMID: 19361589 Clinical Trial.
The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis.
O'Donoghue M, Antman EM, Braunwald E, Murphy SA, Steg PG, Finkelstein A, Penny WF, Fridrich V, McCabe CH, Sabatine MS, Wiviott SD. O'Donoghue M, et al. Among authors: murphy sa. J Am Coll Cardiol. 2009 Aug 18;54(8):678-85. doi: 10.1016/j.jacc.2009.05.025. J Am Coll Cardiol. 2009. PMID: 19679245 Free article. Clinical Trial.
Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) trial.
Murphy SA, Cannon CP, Wiviott SD, McCabe CH, Braunwald E. Murphy SA, et al. J Am Coll Cardiol. 2009 Dec 15;54(25):2358-62. doi: 10.1016/j.jacc.2009.10.005. J Am Coll Cardiol. 2009. PMID: 20082923 Free article. Clinical Trial.
Long-term Safety and Efficacy of Achieving Very Low Levels of Low-Density Lipoprotein Cholesterol : A Prespecified Analysis of the IMPROVE-IT Trial.
Giugliano RP, Wiviott SD, Blazing MA, De Ferrari GM, Park JG, Murphy SA, White JA, Tershakovec AM, Cannon CP, Braunwald E. Giugliano RP, et al. Among authors: murphy sa. JAMA Cardiol. 2017 May 1;2(5):547-555. doi: 10.1001/jamacardio.2017.0083. JAMA Cardiol. 2017. PMID: 28291866 Free PMC article. Clinical Trial.
Inflammatory and Cholesterol Risk in the FOURIER Trial.
Bohula EA, Giugliano RP, Leiter LA, Verma S, Park JG, Sever PS, Lira Pineda A, Honarpour N, Wang H, Murphy SA, Keech A, Pedersen TR, Sabatine MS. Bohula EA, et al. Among authors: murphy sa. Circulation. 2018 Jul 10;138(2):131-140. doi: 10.1161/CIRCULATIONAHA.118.034032. Epub 2018 Mar 12. Circulation. 2018. PMID: 29530884 Free article. Clinical Trial.
662 results